ICR cancer drug programme aims to deliver a step change in cancer treatment

The world’s first ‘Darwinian’ cancer drug programme was launched by the Institute of Cancer Research (ICR), and aims to deliver a step change in cancer treatment. The programme will be run from the ICR’s £75 million state-of-the-art Centre for Cancer Drug Discovery in London. The new cancer drug programme will harness evolutionary science to tackle […]

read more

Avelumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the avelumab (Bavencio) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval is the first by the FDA for an anti-PD-L1 therapy as part of a combination treatment for patients with advanced RCC. Around 20-30% of people […]

read more

Percutaneous cryoablation for stage T1b tumours

A recent study published in Cardiovascular and Interventional Radiology this month looked at the use of percutaneous cryoablation for stage T1b (4.1-7.0 cm) renal cell carcinoma (RCC). This non-invasive technique, which involves ‘freezing’ the tumour using fine needles inserted through the skin (percutaneous), has not yet been widely adopted. The current study investigated the safety, […]

read more

PD-1, PD-L1 and PD-L2 levels differ between patients

In a recent study, published in BMC Cancer last month, it was reported that the levels of the programmed cell death proteins PD-1, PD-L1 and PD-L2 varied between primary tumour, metastases and site of metastases. For example, PD-L1 was higher in metastatic tumours compared with primary tumours, and PD-1 expression was 65.3% in lung/lymph metastases […]

read more

Effect of treatment delay on outcomes in metastatic kidney cancer

A recent study published in Science Direct followed patients with metastatic renal cell carcinoma (RCC), who were ineligible for active surveillance, to determine whether a delay in receiving first-line treatment affected outcomes. In the study, the overall median treatment delay was 6.3 weeks. Patients with bone metastases and advanced disease at diagnosis were more likely […]

read more

Clinical characteristics and genomic alterations associated with outcome in chromophobe RCC

A recent study by researchers in New York, USA, and published in Clinical Genitourinary Cancer identified gene alterations and clinical characteristics that could help predict outcome in patients with a rare form of renal cell carcinoma (RCC) called chromophobe RCC. These gene alterations and clinical characteristics could also help identify potential targeted therapy options in […]

read more

Advances in systemic treatments for kidney cancer

In this video interview, Professor Jens Bedke, Professor of Urology and Vice Chairman at the Department of Urology, University Hospital Tuebingen, Germany, discusses the advances in first-line treatment of renal cell carcinoma (RCC) from monotherapy, which has been the standard of care for the treatment of RCC, to combination therapies. First-line treatment with a combination […]

read more

CAR can be used to indicate survival in kidney cancer patients

A recent study with Japanese patients, published in Urologic Oncology last month, provides evidence to suggest that the ratio of two proteins in the blood (C-reactive protein and albumin ratio, CAR) before surgery is an independent prognostic indicator of overall survival, cancer-specific survival and recurrence-free survival for patients with renal cell carcinoma (RCC). Because CAR […]

read more

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more

Overall survival data for kidney cancer patients treated with high dose interleukin-2

A retrospective study recently reported in Journal for Immunotherapy of Cancer looked at the survival of renal cell carcinoma (RCC) patients who were assessed using the International Metastatic RCC Database Consortium (IMDC) for RCC risk and treated with high dose interleukin-2 (IL-2). These patients were entered on the PROCLAIMSM data base. The patients were followed […]

read more
Showing 1 to 10 of 514 results
  TOP